Compare Hershey Co (HSY) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Hershey Co trades at $165.63 (market cap $32.76B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Hershey Co is far larger — about 33.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Hershey Co pays a 3.56% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HSY | MRVI | |
|---|---|---|
Market Cap | $32.76B | $972.90M |
Volume | 1,118,576 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $9.00 |
52-Week Low | $157.61 | $2.83 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $37.89B | $1.08B |
Dividend Yield | 3.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSY trades at $164.25, up 0.25% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 38.38% gross margins and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus is mixed with 68.57% hold ratings but a $203.69 price target suggesting 24% upside. Recent news highlights dividend resumption and international leadership changes.
HSY presents a value opportunity with reasonable valuation multiples (P/E 22.27) and dividend yield, but faces headwinds from cocoa cost pressures and technical weakness. The stock's investment case hinges on margin recovery and successful execution of brand investments amid competitive consumer staples landscape.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
